August 22, 2025 — ABVC BioPharma, Inc. has received an additional $100,000 licensing payment from ForSeeCon Eye Corporation under the global licensing agreement covering the Company’s innovative vitreous substitute, Vitargus®.
With this latest payment, ABVC has now collected a cumulative $495,000 in cash licensing payments from ForSeeCon. The overall licensing structure includes $30 million already delivered in equity consideration, represented by 5 million ForSeeCon shares based on an internal equity valuation; $3.5 million in total cash licensing payments, of which $495,000 has been received to date; and up to $60 million in sales royalties (5% of net sales), payable if Vitargus® reaches commercialization.
Vitargus® is believed to be the world’s first biodegradable vitreous substitute designed to replace the gel-like substance in the eye during retinal detachment surgery. Unlike current silicone oil or gas bubble solutions, Vitargus® is naturally absorbed and allows patients to maintain upright vision during recovery, eliminating the need for prolonged face-down positioning.
Dr. Uttam Patil, ABVC’s Chief Executive Officer, stated that this milestone payment from ForSeeCon highlights the continued progress of the Vitargus® licensing collaboration. Jerry Chang, CEO of ForSeeCon Eye Corporation, added that Vitargus continues to generate interest globally and that their milestone payment reflects confidence in the product’s regulatory and commercial trajectory.
Uttam Patil can be reached by email at uttam@ambrivis.com.
Source: ABVC BioPharma
